Related Experiment Videos
Oncolytic Virotherapy: A Contest between Apples and Oranges
Stephen J Russell1, Kah-Whye Peng1
1Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Summary
Oncolytic viruses (OVs) are engineered to target and destroy cancer cells, stimulating an immune response against tumors. The study reviews the progress and future directions of OV therapies, including talimogene laherparepvec (T-VEC).
Area of Science:
- Oncolytic virotherapy
- Cancer immunotherapy
- Viral oncology
Background:
- Viruses can be engineered for selective replication in tumors and modified for therapeutic transgene expression.
- Oncolytic viruses (OVs) are administered locally or intravenously, spreading within tumor sites.
- OV-infected tumor cells release antigens, initiating an immune response against cancer cells.
Purpose of the Study:
- To examine the talimogene laherparepvec (T-VEC) paradigm in oncolytic virotherapy.
- To review the development of next-generation OVs for cancer treatment.
- To explore the combination of OVs with immunomodulatory agents.
Main Methods:
- Review of clinical data and research on oncolytic viruses.
- Analysis of talimogene laherparepvec (T-VEC) as a therapeutic model.
- Examination of strategies for developing novel OVs for local and systemic administration.
Main Results:
- Oncolytic viruses demonstrate potential in cancer treatment, with T-VEC approved for melanoma.
- T-VEC enhances responsiveness to checkpoint inhibitor therapy.
- Ongoing research focuses on next-generation OVs and combination therapies.
Conclusions:
- Oncolytic viruses represent a promising therapeutic strategy for cancer.
- Talimogene laherparepvec (T-VEC) highlights the clinical success of OV therapy.
- Future directions include developing advanced OVs and combining them with other immunotherapies for improved antitumor efficacy.